A new medication found to reduce the chance of the most common types of breast cancer recurring will be available to many ...

For the first time in Australia, a drug that can delay the growth of tumours is available under the Pharmaceutical Benefits ...

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of ...

Ananda Lewis chose alternative breast cancer treatments for years before her death this month. Here’s what she tried and what ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...